Rallybio Corp
For the period ended Dec 31, 2023. Filed Mar 12, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 12, 2024
RLYB$15.76+0.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
| FOR THE YEAR ENDEDDECEMBER 31, | ||
|---|---|---|
| (in thousands, except share and per share amounts) | 2023 | 2022 |
| Operating expenses: | ||
| Research and development | $53,544 | $40,689 |
| General and administrative | 25,388 | 27,195 |
| Total operating expenses | 78,932 | 67,884 |
| Loss from operations | (78,932) | (67,884) |
| Other income: | ||
| Interest income | 6,147 | 1,963 |
| Other income | 262 | 342 |
| Total other income, net | 6,409 | 2,305 |
| Loss before equity in losses of joint venture | (72,523) | (65,579) |
| Loss on investment in joint venture | 2,041 | 1,075 |
| Net loss | $(74,564) | $(66,654) |
| Net loss per common share, basic and diluted | $(1.84) | $(2.09) |
| Weighted-average common shares outstanding, basic and diluted | 40,447,388 | 31,821,311 |
| Other comprehensive gain (loss): | ||
| Net unrealized gain (loss) on marketable securities | 229 | (214) |
| Other comprehensive gain (loss) | 229 | (214) |
| Comprehensive loss | $(74,335) | $(66,868) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.